Orchestra BioMed Holdings (OBIO) Other Accumulated Expenses (2022 - 2026)

Orchestra BioMed Holdings (OBIO) has 5 years of Other Accumulated Expenses data on file, last reported at $2.7 million in Q1 2026.

• On a quarterly basis, Other Accumulated Expenses rose 142.36% year-over-year to $2.7 million in Q1 2026; TTM through Mar 2026 was $2.7 million, a 142.36% increase from a year earlier, with the FY2025 full-year figure at $1.6 million, up 172.71% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $2.7 million, up from $1.6 million in the prior quarter.
• Over the last five years, Other Accumulated Expenses for OBIO reached as high as $2.7 million in Q1 2026 and fell as low as $379000.0 in Q2 2024.
• Historically, Other Accumulated Expenses has averaged $1.2 million across 5 years, with a median of $1.1 million in 2023.
• Across the five-year window, Other Accumulated Expenses sank 61.21% in 2024 and surged 172.71% in 2025, its largest moves.
• Year by year, Other Accumulated Expenses stood at $1.9 million in 2022, then plunged by 43.0% to $1.1 million in 2023, then plunged by 46.34% to $579000.0 in 2024, then jumped by 172.71% to $1.6 million in 2025, then soared by 68.84% to $2.7 million in 2026.
• Per Business Quant data, the three most recent Other Accumulated Expenses figures were $2.7 million in Q1 2026, $1.6 million in Q4 2025, and $1.7 million in Q3 2025.